Sherbrooke Park Advisers LLC Arbutus Biopharma Corp Transaction History
Sherbrooke Park Advisers LLC
- $215 Billion
- Q3 2025
A detailed history of Sherbrooke Park Advisers LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 37,073 shares of ABUS stock, worth $167,569. This represents 0.08% of its overall portfolio holdings.
Number of Shares
37,073
Previous 21,634
71.36%
Holding current value
$167,569
Previous $66.8 Million
151.78%
% of portfolio
0.08%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding ABUS
# of Institutions
194Shares Held
118MCall Options Held
2.67MPut Options Held
693K-
Morgan Stanley New York, NY24.5MShares$111 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$60.3 Million22.38% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$52.2 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY11MShares$49.7 Million0.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.99MShares$40.6 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $678M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...